IT1394302B1 - "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY" - Google Patents

"NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY"

Info

Publication number
IT1394302B1
IT1394302B1 ITMI2009A000887A ITMI20090887A IT1394302B1 IT 1394302 B1 IT1394302 B1 IT 1394302B1 IT MI2009A000887 A ITMI2009A000887 A IT MI2009A000887A IT MI20090887 A ITMI20090887 A IT MI20090887A IT 1394302 B1 IT1394302 B1 IT 1394302B1
Authority
IT
Italy
Prior art keywords
diagnosis
therapy
hybrid particles
new hybrid
new
Prior art date
Application number
ITMI2009A000887A
Other languages
Italian (it)
Inventor
Luigi Tarpani
Loredana Lattarini
Fausto Elisei
Original Assignee
Uni Degli Studi Perugia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Degli Studi Perugia filed Critical Uni Degli Studi Perugia
Priority to ITMI2009A000887A priority Critical patent/IT1394302B1/en
Priority to PCT/IB2010/001145 priority patent/WO2010133941A2/en
Publication of ITMI20090887A1 publication Critical patent/ITMI20090887A1/en
Application granted granted Critical
Publication of IT1394302B1 publication Critical patent/IT1394302B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026Acridine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
ITMI2009A000887A 2009-05-20 2009-05-20 "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY" IT1394302B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITMI2009A000887A IT1394302B1 (en) 2009-05-20 2009-05-20 "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY"
PCT/IB2010/001145 WO2010133941A2 (en) 2009-05-20 2010-05-17 New hybrid particles and their use in diagnostics and therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI2009A000887A IT1394302B1 (en) 2009-05-20 2009-05-20 "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY"

Publications (2)

Publication Number Publication Date
ITMI20090887A1 ITMI20090887A1 (en) 2010-11-21
IT1394302B1 true IT1394302B1 (en) 2012-06-06

Family

ID=41506422

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI2009A000887A IT1394302B1 (en) 2009-05-20 2009-05-20 "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY"

Country Status (2)

Country Link
IT (1) IT1394302B1 (en)
WO (1) WO2010133941A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071535B2 (en) * 2003-09-12 2011-12-06 The Regents Of The University Of California Guanidinium derivatives for improved cellular transport
WO2006102307A2 (en) * 2005-03-21 2006-09-28 University Of Louisville Research Foundation, Inc. Target specific nanoparticles for enhancing optical contrast enhancement and inducing target-specific hyperthermia
WO2008140624A2 (en) * 2006-12-22 2008-11-20 The Board Of Regents Of The University Of Texas System Methods and compositions related to hybird nanoparticles
US8361437B2 (en) * 2007-08-28 2013-01-29 University Of Florida Research Foundation, Inc. Multimodal nanoparticles for non-invasive bio-imaging

Also Published As

Publication number Publication date
WO2010133941A2 (en) 2010-11-25
ITMI20090887A1 (en) 2010-11-21
WO2010133941A3 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
HK1258817A1 (en) Synthetic triterpenoids and methods of use in the treatment of disease
SMT201500206B (en) Spiro-oxindolic compounds and their use as therapeutic agents
SMT201400146B (en) Morpholino pyrimidine and their use in therapy
PT3042910T (en) 2'-spiro-nucleosides for use in the therapy of hepatitis c
SMT201400164B (en) Morpholino pyrimidine and their use in therapy
HK1171458A1 (en) Antibodies against human il 17 and uses thereof il17
IT1391530B1 (en) ACTIVE PARTICLES FOR BIO-ANALYTICAL APPLICATIONS AND METHODS FOR THEIR PREPARATION
HK1146596A1 (en) Use of lingo-4 antagonists in the treatment of conditions involving demyelination lingo-4
IL222605A (en) Apparatus and kit for encapsulating at least one compound in erythrocytes for therapeutic and/or diagnostic use
GB0708585D0 (en) Novel antibody and use in diagnosis and therapy of arthropathies
IL214244A0 (en) Scriptaid isosteres and their use in therapy
IT1398268B1 (en) GLYCEROSOMES AND THEIR USE IN PHARMACEUTICAL AND COSMETIC PREPARATIONS FOR TOPICAL USE
BR112013008704A2 (en) "waste pick-up coil dispenser and methods of use"
IT1401531B1 (en) SYSTEM CAN BE USED IN TWO MODES
IL212672A (en) Cycloundecadepsipeptide compounds and use of said compounds in the manufacture of medicaments
ZA201300183B (en) " backing having three -layer structure and aqueous patch using the backing "
GB0920258D0 (en) New medical agents and use thereof
FI20106220A0 (en) Procedure and arrangement in connection with wheelchair operation
EP2449126A4 (en) Novel antibodies and their uses in therapeutic and diagnostic methods
BRPI0923886A2 (en) "use of ammonium chloride in therapy"
PT2670769T (en) R2r1/2 in diagnosis and therapy
BRPI1012325A2 (en) use of microrna-199b-5p in the medical and diagnostic field. "
HK1182397A1 (en) New octapeptide compounds and their use in therapy
IT1394302B1 (en) "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY"
BR112013010061A2 (en) "pharmaceutical composition, composition and use"